Repository logo
 

Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership.

Simple item page
cam.issuedOnline2022-06-15
dc.contributor.authorHarris, Tess
dc.contributor.authorBridges, Hannah R
dc.contributor.authorBrown, Wendy D
dc.contributor.authorO'Brien, Natasha L
dc.contributor.authorDaly, Ann C
dc.contributor.authorJindal, Bharat K
dc.contributor.authorMundy, Gillian S
dc.contributor.authorOng, Albert
dc.contributor.authorPower, Albert J
dc.contributor.authorSandford, Richard N
dc.contributor.authorSayer, John
dc.contributor.authorSimms, Roslyn J
dc.contributor.authorWilson, Patricia D
dc.contributor.authorWinyard, Paul JD
dc.contributor.authorTarpey, Maryrose
dc.contributor.orcidHarris, Tess [0000-0003-3659-7438]
dc.contributor.orcidOng, Albert [0000-0002-7211-5400]
dc.date.accessioned2022-06-29T19:42:40Z
dc.date.available2022-06-29T19:42:40Z
dc.date.issued2022-06-15
dc.date.submitted2021-09-15
dc.date.updated2022-06-29T19:42:39Z
dc.description.abstractOBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney condition, accounting for 7%-10% of patients with kidney failure. Fundamental basic science and clinical research on ADPKD is underway worldwide but no one has yet considered which areas should be prioritised to maximise returns from limited future funding. The Polycystic Kidney Disease Charity began a priority setting partnership with the James Lind Alliance (JLA) in the UK in 2019-2020 to identify areas of uncertainty in the ADPKD care pathway and allow patients, carers and healthcare professionals to rank the 10 most important questions for research. DESIGN: The scope covered ADPKD diagnosis and management, identifying new treatments to prevent/slow disease progression and practical, integrated patient support (https://pkdcharity.org.uk/research/for-researchers/adpkd-research-priorities). We used adapted JLA methodology. Initially, an independent information specialist collated uncertainties in ADPKD care from recent consensus conference proceedings and additional literature. These were refined into indicative questions with Steering Group oversight. Finally, the 10 most important questions were established via a survey and online consensus workshop. SETTING: UK. PARTICIPANTS: 747 survey respondents (76% patients, 13% carers, 11% healthcare professionals); 23 workshop attendees. RESULTS: 117 uncertainties in ADPKD care were identified and refined into 35 indicative questions. A shortlist of 17 questions was established through the survey. Workshop participants reached agreement on the top 10 ranking. The top three questions prioritised by patients, carers and healthcare professionals centred around slowing disease progression, identifying persons for early treatment and organising care to improve outcomes. CONCLUSIONS: Our shortlist reflects the varied physical, psychological and practical challenges of living with and treating ADPKD, and perceived gaps in knowledge that impair optimal care. We propose that future ADPKD research funding takes these priorities into account to focus on the most important areas and to maximise improvements in ADPKD outcomes.
dc.identifier.doi10.17863/CAM.85855
dc.identifier.eissn2044-6055
dc.identifier.issn2044-6055
dc.identifier.otherbmjopen-2021-055780
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338442
dc.languageen
dc.language.isoeng
dc.publisherBMJ
dc.publisher.urlhttp://dx.doi.org/10.1136/bmjopen-2021-055780
dc.subjecthepatology
dc.subjectnephrology
dc.subjectpain management
dc.subjectBiomedical Research
dc.subjectCaregivers
dc.subjectDisease Progression
dc.subjectHealth Priorities
dc.subjectHumans
dc.subjectPolycystic Kidney, Autosomal Dominant
dc.subjectUnited Kingdom
dc.titleResearch priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership.
dc.typeArticle
dcterms.dateAccepted2022-05-31
prism.issueIdentifier6
prism.publicationNameBMJ Open
prism.volume12
pubs.funder-project-idPolycystic Kidney Disease Charity (N/A)
rioxxterms.freetoread.startdate2022-06-15
rioxxterms.licenseref.startdate2022-06-15
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1136/bmjopen-2021-055780

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
bmjopen-2021-055780.pdf
Size:
436.59 KB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
http://creativecommons.org/licenses/by-nc/4.0/
Download
No Thumbnail Available
Name:
bmjopen-2021-055780.xml
Size:
74.49 KB
Format:
Extensible Markup Language
Description:
Bibliographic metadata
Licence
http://creativecommons.org/licenses/by-nc/4.0/
Download

Collections

Jisc Publications Router